Successful treatment of pyoderma gangrenosum with anakinra in a patient with Wiskott-Aldrich syndrome

Dermatol Ther. 2018 Mar;31(2):e12582. doi: 10.1111/dth.12582. Epub 2017 Dec 7.

Authors

Santo Raffaele Mercuri¹, Giovanni Paolino^{1

2}, Eduardo De Flammineis¹, Dario Didona³, Pina Brianti¹

Affiliations

¹ Unit of Dermatology and Cosmetology, IRCCS University Vita-Salute San Raffaele, Milan, Italy.
² Department of Dermatology, La Sapienza University of Rome, Italy.
³ First Division of Dermatology, IRCCS Istituto Dermopatico dell'Immacolata, Rome, Italy.

PMID: 29214738
DOI: 10.1111/dth.12582

No abstract available

Publication types

Case Reports
Letter
Retracted Publication

MeSH terms

Adolescent
Anti-Inflammatory Agents / therapeutic use*
Humans
Immunocompromised Host
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
Male
Pyoderma Gangrenosum / diagnosis
Pyoderma Gangrenosum / drug therapy*
Pyoderma Gangrenosum / immunology
Treatment Outcome
Wiskott-Aldrich Syndrome / diagnosis
Wiskott-Aldrich Syndrome / genetics
Wiskott-Aldrich Syndrome / immunology*
Wiskott-Aldrich Syndrome / therapy
Wound Healing

Substances

Anti-Inflammatory Agents
Interleukin 1 Receptor Antagonist Protein